Picture [iito] Life Science Business Portals Media Data 2022 2 650x100px
Organisation › Details

Jeito Capital (Group)

Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients' access in Europe & the United States. Jeito Capital has €534 million under management. Jeito Capital is based in Paris with a presence in Europe and the United States. *


Period Start 2018-06-25 established
Products Industry venture capital
  Industry 2 LIFE SCIENCES
Persons Person Tordjman, Rafaèle (Jeito Capital 201806– President + Founder before Sofinnova Partners 2001–2017)
  Person 2 Clancy, Annette (Enyo Pharma 201806 Chair of Board of Directors)
Region Region Paris
  Country France
  Street 33 rue La Fayette
  City 75009 Paris
    Address record changed: 2021-07-10
Basic data Employees n. a.
  Currency EUR
  Annual sales 534,000,000 (capital under management (2021) 2021-11-29)
    * Document for �About Section�: Quell Therapeutics Ltd.. (11/29/21). "Press Release: Quell Therapeutics Raises $156 Million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform". London & Boston,
Record changed: 2021-11-29


Picture [iito] Fighting Customers 650x100px

More documents for Jeito Capital (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top